143 related articles for article (PubMed ID: 29851903)
1. In vitro effects of a kaolin-coated hemostatic dressing on anticoagulated blood.
Cripps MW; Cornelius CC; Nakonezny PA; Vazquez N; Wey JC; Gales PE
J Trauma Acute Care Surg; 2018 Sep; 85(3):485-490. PubMed ID: 29851903
[TBL] [Abstract][Full Text] [Related]
2. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.
Bar J; David A; Khader T; Mulcare M; Tedeschi C
Prehosp Disaster Med; 2017 Oct; 32(5):580-587. PubMed ID: 28625215
[TBL] [Abstract][Full Text] [Related]
3. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
[TBL] [Abstract][Full Text] [Related]
5. Measuring Direct Oral Anticoagulants.
Gosselin RC; Douxfils J
Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
8. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists.
Kopytek M; Zabczyk M; Natorska J; Siudut J; Malinowski KP; Ptaszek P; Glajcar A; Goralczyk T; Undas A
J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019123
[TBL] [Abstract][Full Text] [Related]
9. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
10. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
12. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
13. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
[TBL] [Abstract][Full Text] [Related]
14. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
Adcock DM; Gosselin R
Thromb Res; 2015 Jul; 136(1):7-12. PubMed ID: 25981138
[TBL] [Abstract][Full Text] [Related]
15. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
16. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
17. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Dias JD; Norem K; Doorneweerd DD; Thurer RL; Popovsky MA; Omert LA
Arch Pathol Lab Med; 2015 May; 139(5):665-73. PubMed ID: 25927150
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
Kim YS; Murkin JM; Adams SJ
Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
[TBL] [Abstract][Full Text] [Related]
19. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring options and reversal agents for oral anticoagulants].
Thorup SB; Husted SE; Vang ML
Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
